- Home
- VMD vs RIGL Comparison
VMD vs RIGL Comparison
Compare VMD & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VMD | RIGL |
|---|---|---|
| Founded | 2006 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 277.5M | 537.6M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | VMD | RIGL |
|---|---|---|
| Price | $7.44 | $42.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $43.20 |
| AVG Volume (30 Days) | 147.9K | ★ 506.3K |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 35.92 | ★ 2698.26 |
| EPS | 0.34 | ★ 6.20 |
| Revenue | $254,794,000.00 | ★ $282,076,000.00 |
| Revenue This Year | $20.05 | $65.53 |
| Revenue Next Year | $17.44 | $0.22 |
| P/E Ratio | $21.49 | ★ $7.10 |
| Revenue Growth | 18.89 | ★ 79.13 |
| 52 Week Low | $5.93 | $15.50 |
| 52 Week High | $8.62 | $52.24 |
Technical Indicators
Market Signals| Indicator | VMD | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 61.90 | 49.66 |
| Support Level | $7.24 | $40.52 |
| Resistance Level | $7.36 | $44.85 |
| Average True Range (ATR) | 0.20 | 1.87 |
| MACD | -0.00 | -0.30 |
| Stochastic Oscillator | 69.27 | 47.76 |
Price Performance
Historical ComparisonAbout VMD Viemed Healthcare Inc.
Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.